Erasca (ERAS) Free Cash Flow (2020 - 2026)
Erasca posted quarterly Free Cash Flow of -$27.4 million for Q1 2026, up 13.34% year-on-year from -$24.2 million in Q1 2025, and down 26.24% on a QoQ basis from -$21.7 million in Q4 2025.
Erasca (ERAS) has 7 years of Free Cash Flow data on file, last reported at -$27.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 13.34% year-over-year to -$27.4 million; the trailing twelve-month figure through Mar 2026 stood at -$91.4 million (up 15.26% YoY), and the FY2025 full-year result was -$95.6 million, up 12.69% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$27.4 million, down from -$21.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$20.6 million in Q2 2025 and bottomed at -$33.3 million in Q1 2024.
- The 5-year median for Free Cash Flow is -$26.2 million (2023), against an average of -$26.7 million.
- The widest annual swing landed in 2022, when Free Cash Flow slumped 109.92%; it then climbed 29.58% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$27.2 million in 2022, then climbed by 8.69% to -$24.9 million in 2023, then grew by 1.23% to -$24.6 million in 2024, then climbed by 11.58% to -$21.7 million in 2025, then retreated by 26.24% to -$27.4 million in 2026.
- The last three Free Cash Flow figures came in at -$27.4 million (Q1 2026), -$21.7 million (Q4 2025), and -$21.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -27.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.42 Mn |
| Mar 31, 2026 | -27.42 Mn |
| Dec 31, 2025 | -21.72 Mn |
| Dec 31, 2025 | -21.72 Mn |
| Sep 30, 2025 | -21.66 Mn |
| Sep 30, 2025 | -21.66 Mn |
| Jun 30, 2025 | -20.56 Mn |
| Jun 30, 2025 | -20.56 Mn |
| Mar 31, 2025 | -31.64 Mn |
| Mar 31, 2025 | -31.64 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Sep 30, 2024 | -22.42 Mn |
| Sep 30, 2024 | -22.42 Mn |
| Jun 30, 2024 | -29.20 Mn |
| Jun 30, 2024 | -29.20 Mn |
| Mar 31, 2024 | -33.29 Mn |
| Mar 31, 2024 | -33.29 Mn |
| Dec 31, 2023 | -24.87 Mn |
| Dec 31, 2023 | -24.87 Mn |
| Sep 30, 2023 | -24.36 Mn |
| Sep 30, 2023 | -24.36 Mn |
| Jun 30, 2023 | -26.20 Mn |
| Jun 30, 2023 | -26.20 Mn |
| Mar 31, 2023 | -27.56 Mn |
| Mar 31, 2023 | -27.56 Mn |
| Dec 31, 2022 | -27.24 Mn |
| Dec 31, 2022 | -27.24 Mn |
| Sep 30, 2022 | -25.74 Mn |
| Sep 30, 2022 | -25.74 Mn |
| Jun 30, 2022 | -31.70 Mn |
| Jun 30, 2022 | -31.70 Mn |
| Mar 31, 2022 | -33.14 Mn |
| Mar 31, 2022 | -33.14 Mn |
| Dec 31, 2021 | -28.31 Mn |
| Dec 31, 2021 | -28.31 Mn |
| Sep 30, 2021 | -27.89 Mn |
| Sep 30, 2021 | -27.89 Mn |
| Jun 30, 2021 | -18.81 Mn |
| Jun 30, 2021 | -18.81 Mn |
| Mar 31, 2021 | -15.79 Mn |
| Mar 31, 2021 | -15.79 Mn |
| Dec 31, 2020 | -13.12 Mn |
| Dec 31, 2020 | -13.12 Mn |
| Sep 30, 2020 | -7.63 Mn |
| Sep 30, 2020 | -7.63 Mn |